Protecting Health. Strengthening Canada’s Preparedness.
For 50 years, the Vaccine and Infectious Disease Organization (VIDO) has helped protect people, animals, and economies from infectious diseases. Through vaccine development, high-containment research, and global partnerships, VIDO translates science into real-world solutions.
VIDO's Impact
Protecting public health
VIDO develops vaccines and countermeasures to emerging infectious diseases, helping Canada respond quickly to future health threats.
Related stories
Supporting Food Security
VIDO’s research protects livestock and wildlife from disease, supporting food security and Canada’s agricultural economy.Related stories
Strengthening Canada’s Sovereignty & Readiness
VIDO’s advanced containment facilities and scientific expertise give Canada the capacity to study high-risk pathogens and develop solutions.Related stories
Global Parnerships
VIDO collaborates with governments, industry, and research organizations around the world to accelerate vaccine and therapeutic development.
- MOUs with both CFIA and PHAC
- Collaborations on SARS-CoV-2, ASF and HPAI (cattle)
- Emergency and surge backup for Government of Canada
- Only Canadian academic institution to be awarded direct CEPI funding
- 9th CEPI Preclinical Network selected globally
- Selected as part of the CEPI Adjuvant Network
INTERCEPTOR
- Joined global network of 19 high-containment labs to strengthen pandemic preparedness
- Leveraging CL3–CL4 capabilities and vaccine expertise to advance coordinated international response
International Livestock Research Institute (ILRI) / Kenya Agricultural & Livestock Research Organization (KALRO)
- Developed contagious bovine pleuropnemonia prototype vaccine
- Historic training exchanges
- Expanding partnership into new areas
- Longstanding global health partnership
- Tuberculosis identified as a priority vaccine project
- Supported Canada joining IVI as a member country
- Awarded Canada’s only biotech-focused test centre
- Expanding role in defence-related research
- Increasing international visibility
- Active collaboration on ASF and B-cell repertoire research
- Scientist and training exchanges
- Partnering on vaccine manufacturing assets
- Partnered on COVID-19 vaccine development
- First use of SEPIVAC SWE adjuvant in humans
- Expanding collaboration to include additional key adjuvants
Looking Ahead
Emerging infectious diseases continue to impact health systems, economies, and food security worldwide. By advancing research, training experts, and expanding national research infrastructure, VIDO is helping ensure Canada is ready for the next pandemic.